



This is an English translation of a Hebrew immediate report that was published on September 28, 2022 (Ref No.: 2022-01-121342) (hereafter: the “**Hebrew Version**”). This English version is only for convenience purposes. This is not an official translation and has no binding force. Whilst reasonable care and skill have been exercised in the preparation hereof, no translation can ever perfectly reflect the Hebrew Version. In the event of any discrepancy between the Hebrew Version and this translation, the Hebrew Version shall prevail.

BEEIO HONEY LTD
(the “**Company**”)

September 28, 2022

To:
Israel Securities Authority
www.isa.gov.il

To:
Tel Aviv Stock Exchange Ltd .
www.tase.co.il

Dear Sirs and Madams,

Re: **Success in the production of cultivated honey with proven anti-cancerous properties**

The Company is honored to inform its shareholders that on September 25, 2022, Beeio Honey Technologies Ltd., a private company wholly owned by the Company (the “**Subsidiary**”), successfully completed an *in vitro* experiment (hereinafter: the “**Experiment**”) in a cellular model of skin cancer (melanoma) to establish the anti-cancerous properties of cultivated coffee honey enriched with cultivated royal jelly protein that has been produced using the production facility set up in its laboratories. The Experiment was performed on behalf of the Subsidiary by a certified external laboratory that provides GLP research services (Good Laboratory Practice), which confirmed its results as founded and as having a high statistical significance (P-value < 0.001).

The success of the Experiment proves that the Subsidiary is capable of producing cultivated honey (cultivated coffee honey enriched with cultivated royal jelly protein) with proven anti-cancerous properties in a consistent, effective way using the production facility set up in its laboratories, similarly to commercial coffee honey, as the findings of the Experiment show.



The primary purpose of the Experiment reported here was to evaluate *in vitro* the anti-cancerous properties of the Company's cultivated honey (cultivated coffee honey enriched with cultivated royal jelly protein) compared to commercially available natural coffee honey. To this end, human tissue culture cells were treated with honey, and the impact on cell viability was measured. The test was performed on two human cell lines – normal and cancerous (melanoma). The results of the Experiment in the cellular model showed that the cultivated honey developed by the Company caused, in certain concentrations to mortality of approximately 50% of the skin cancer cells with statistical significance, and therefore demonstrates proven anti-cancerous efficiency, without compromising the viability of the normal skin cells, similarly to the commercial coffee honey tested in the Experiment.

Honey is a functional food with health properties. The health advantages of honey and of royal jelly protein have been well researched¹⁻³. The most known medical properties of honey are anti-microbial activity⁴⁻⁵, presence of anti-oxidants⁶, wound healing^{7,8}, and anti-cancerous properties⁹⁻¹⁰. Low pH, high sugar content (osmolality), hydrogen peroxide (H₂O₂), polyphenols, and various proteins/peptides, are all main contributors to the health properties of honey^{1,2}. The anti-cancerous properties attributed to honey are particularly of interest, both for systemic and local treatments, e.g. for treating skin cancer⁹⁻¹². Proving the anti-cancerous properties of the cultivated honey produced by Bee-io Honey in its facilities is an additional significant milestone in the development of functional cultivated honey which is similar in composition and properties to pure honey that will be used as "super food", enrich human nutrition, and serve as high quality raw material in the honey industry and in additional industries, such as pharma, cosmetics, etc.

This successful research is an important stage in establishing the health advantages of the Company's enriched cultivated honey, and in demonstrating the Company's ability to accurately mimic the composition of honey while keeping its health properties, independently of bees. The success in the Experiment is in accordance with the work plan agreed upon between the Company and the Subsidiary and is expected to allow the Subsidiary to continue developing and improving the production capabilities of cultivated honey with proven anti-cancerous properties in an industrial scale. The Company estimates that some of the findings and/or processes and/or research methods it has developed thus far, and which may be developed as the Company progresses with its purposes, will be used as intellectual property in addition to the intellectual property it currently has.



The information mentioned in this notice is “Forward Looking Information” as defined in The Securities Law, 5728-1968, based on the information known to the Company as of this date, and on estimates and predictions which their realization depends, among others, on factors that are outside of the Company’s control. To be noted, the Company is a research and development company and as such, its estimations might be realized in a different manner, if at all, given that the Company’s research is preliminary and precedential.

Sincerely,
OFIR DVASH, CEO
BEEIO HONEY LTD.

1. Rao, P. V., Krishnan, K. T., Salleh, N. & Gan, S. H. Biological and therapeutic effects of honey produced by honey bees and stingless bees: A comparative review. *Revista Brasileira de Farmacognosia* vol. 26 657–664 Preprint at <https://doi.org/10.1016/j.bjp.2016.01.012> (2016).
2. Bogdanov, S., Jurendic, T., Sieber, R. & Gallmann, P. Honey for nutrition and health: A review. *J Am Coll Nutr* **27**, 677–689 (2008).
3. Bansal, V., Medhi, B. & Pandhi, P. Honey--a remedy rediscovered and its therapeutic utility. *Kathmandu Univ Med J (KUMJ)* **3**, 305–309 (2005).
4. Aurongzeb, M. & Kamran Azim, M. Antimicrobial properties of natural honey: a review of the literature. *J. Biochem. Mol. Biol* **44**, 118–124 (2011).
5. Kwakman, P. H. S. *et al.* Medical-grade honey enriched with antimicrobial peptides has enhanced activity against antibiotic-resistant pathogens. *European Journal of Clinical Microbiology and Infectious Diseases* **30**, 251–257 (2011).
6. Erejuwa, O. O., Sulaiman, S. A. & Ab Wahab, M. S. Honey: A Novel Antioxidant. *Molecules* **2012**, Vol. 17, Pages 4400-4423 **17**, 4400–4423 (2012).
7. Moore, O. A. *et al.* *Systematic review of the use of honey as a wound dressing.* *BMC Complementary and Alternative Medicine* vol. 1 <http://www.biomedcentral.com/1472-6882/1/2> (2001).
8. Kim, J. *et al.* Royal jelly enhances migration of human dermal fibroblasts and alters the levels of cholesterol and sphinganine in an in vitro wound healing model. *Nutr Res Pract* **4**, 362 (2010).
9. Waheed, M. *et al.* Honey and cancer: A mechanistic review. *Clinical Nutrition* vol. 38 2499–2503 Preprint at <https://doi.org/10.1016/j.clnu.2018.12.019> (2019).
10. Yamauchi, K., Kogashiwa, Y., Moro, Y. & Kohno, N. The effect of topical application of royal jelly on chemoradiotherapy-induced mucositis in head and neck cancer: a preliminary study. *Int J Otolaryngol* **2014**, 1–5 (2014).
11. Barbosa, N. S. & Kalaaji, A. N. CAM use in dermatology. Is there a potential role for honey, green tea, and vitamin C? *Complement Ther Clin Pract* **20**, 11–15 (2014).
12. Erejuwa, O. O., Sulaiman, S. A. & Ab Wahab, M. S. Effects of Honey and Its Mechanisms of Action on the Development and Progression of Cancer. *Molecules* **2014**, Vol. 19, Pages 2497-2522 **19**, 2497–2522 (2014).